Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISA 2024 | The importance of early diagnosis in AL amyloidosis to improve outcomes for patients

In this video, Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, discusses the importance of early diagnosis in light chain (AL) amyloidosis, which is crucial to improve outcomes for patients. Diagnosing patients at a later stage in their disease can limit the treatment options available, and Dr Nuvolone highlights the value of early screening and monitoring of various biomarkers. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.